Literature DB >> 23673905

Overview of parametric survival analysis for health-economic applications.

K Jack Ishak1, Noemi Kreif, Agnes Benedict, Noemi Muszbek.   

Abstract

Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric survival analysis methods can be applied to identify an appropriate statistical model for the observed data, which can then be extrapolated to derive a complete time-to-event curve. This paper describes the properties of the most commonly used statistical distributions as a basis for these models and describes an objective process of identifying the most suitable parametric distribution in a given dataset. The approach can be applied with both individual-patient data as well as with survival probabilities derived from published Kaplan-Meier curves. Both are illustrated with analyses of overall survival from the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol trial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673905     DOI: 10.1007/s40273-013-0064-3

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  20 in total

1.  Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2002-08-15       Impact factor: 2.373

2.  Survival models in health economic evaluations: balancing fit and parsimony to improve prediction.

Authors:  Christopher H Jackson; Linda D Sharples; Simon G Thompson
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

Review 3.  Methodological issues in the economic analysis of cancer treatments.

Authors:  Paul Tappenden; Jim Chilcott; Sue Ward; Simon Eggington; Daniel Hind; Silvia Hummel
Journal:  Eur J Cancer       Date:  2006-10-04       Impact factor: 9.162

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.

Authors:  Samuel Aballéa; Jeremy V M Chancellor; Maria Raikou; Michael F Drummond; Milton C Weinstein; Sophia Jourdan; John Bridgewater
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

6.  The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kojiro Shimozuma; Yasuo Ohashi; Kiichiro Tsutani
Journal:  Breast Cancer Res Treat       Date:  2007-07-28       Impact factor: 4.872

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

9.  Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up.

Authors:  E J O Soini; J A Martikainen; T Nousiainen
Journal:  Ann Oncol       Date:  2010-12-06       Impact factor: 32.976

10.  Accounting for uncertainty in health economic decision models by using model averaging.

Authors:  Christopher H Jackson; Simon G Thompson; Linda D Sharples
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2009-04       Impact factor: 2.483

View more
  29 in total

1.  Simulation and matching-based approaches for indirect comparison of treatments.

Authors:  K Jack Ishak; Irina Proskorovsky; Agnes Benedict
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

2.  Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal".

Authors:  Odette Reifsnider; Fiona Hall; Sonja Sorensen; Irina Proskorovsky; Isabelle Girod; Jennifer Lee
Journal:  Pharmacoeconomics       Date:  2017-06       Impact factor: 4.981

3.  Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?

Authors:  John W Stevens
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 4.  Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.

Authors:  Kevin Marsh; Peng Xu; Panagiotis Orfanos; James Gordon; Ingolf Griebsch
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 5.  A primer on marginal effects--Part I: Theory and formulae.

Authors:  Eberechukwu Onukwugha; Jason Bergtold; Rahul Jain
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

6.  A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis.

Authors:  Sandjar Djalalov; Jaclyn Beca; Emmanuel M Ewara; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

7.  Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study.

Authors:  Uwe Bieri; Kerstin Hübel; Harald Seeger; Girish S Kulkarni; Tullio Sulser; Thomas Hermanns; Marian S Wettstein
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-07       Impact factor: 8.237

Review 8.  Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges.

Authors:  Kevin Marsh; Peng Xu; Panagiotis Orfanos; Agnes Benedict; Kamal Desai; Ingolf Griebsch
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

9.  Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.

Authors:  E M Ewara; G S Zaric; S Welch; S Sarma
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

10.  Long-Term Survival Following Traumatic Brain Injury: A Population-Based Parametric Survival Analysis.

Authors:  Gordon W Fuller; Jeanine Ransom; Jay Mandrekar; Allen W Brown
Journal:  Neuroepidemiology       Date:  2016-05-11       Impact factor: 3.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.